• Vaxcyte, Inc. recently dosed the first participant in its Phase 1, randomized, double-blind, placebo-controlled trial of VAX-A1, an investigational Group A Streptococcus vaccine candidate being studied in about 80 healthy adults in Australia to assess safety, tolerability and early immune responses.
• This first-in-human study marks Vaxcyte’s entry into Group A Strep prevention, an area with no approved vaccines despite hundreds of millions of annual cases and a significant global health burden.
• We’ll now examine how launching this first-in-human VAX-A1 trial, alongside Vaxcyte’s existing pneumococcal programs, may influence the company’s investment narrative.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

Vaxcyte Investment Narrative Recap

To own Vaxcyte, you have to believe that its pneumococcal franchise, led by VAX-31, will eventually convert late stage trial success into real commercial revenue, while its Group A Strep program becomes a meaningful second pillar over time. The new first in human VAX A1 trial is an important pipeline milestone, but it does not change that the key near term catalyst is still OPUS 1 Phase 3 data in late 2026, or that the biggest risk remains high cash burn before any revenue.

The VAX A1 initiation sits alongside Vaxcyte’s March 2026 update that all three adult OPUS Phase 3 trials of VAX 31 have completed enrollment, with OPUS 1 topline results expected in the fourth quarter of 2026. Together, these milestones frame a period where clinical readouts across pneumococcal and Group A Strep will shape how realistic past analyst expectations around future revenue and financing needs may prove.

Yet even if VAX A1 progresses smoothly, investors should be aware that...

Vaxcyte's narrative projects $224.6 million revenue and $28.1 million earnings by 2029. This implies an earnings increase of about $794.7 million from -$766.6 million today.

Uncover how Vaxcyte's forecasts yield a $109.00 fair value, a 124% upside to its current price.

Exploring Other Perspectives

Before this VAX A1 news, the most optimistic analysts were already assuming revenue could reach about US$423.8 million by 2029, so compared with the baseline view they see the Group A Strep program and OPUS adult trials as opening a far bigger long term opportunity, reminding you that reasonable people can hold very different expectations about how this story plays out.

Explore 3 other fair value estimates on Vaxcyte - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Vaxcyte research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Vaxcyte research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vaxcyte's overall financial health at a glance.

Want Some Alternatives?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Find 45 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.